Blepharoconjunctivitis — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for blepharoconjunctivitis. 31 active patents protecting 3 drugs from 2+ originators. First major cliff: 2032. Daily refresh.

3
Approved drugs
31
Active US patents
61/100
Avg vulnerability
—
Annual revenue covered

Originators in Blepharoconjunctivitis

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Generic (originally Merck/Upjohn) 29 patents Novartis 2 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating blepharoconjunctivitis. Each bar = one year. Y-axis scaled to peak year (7 patents).

2
27
2
28
3
30
5
32
4
33
7
34
1
36
3
37
1
39
1
41

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Decadron
dexamethasone
 Generic (originally Merck) 15 46 — 2027-12-19
Cortef
hydrocortisone
 Generic (originally Merck/Upjohn) 14 64 — 2032-11-19
Tobi
tobramycin
 Novartis 2 72 — 2028-09-12

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
8869794 Tobi method of use 75 2028-09-12
11904046 Cortef method of use 75 2043-02-23
12133914 Cortef method of use 75 2043-02-23
10207066 Tobi method of use 68 2030-11-04
8101582 Decadron method of use 63 2027-12-19
7795316 Decadron method of use 63 2028-08-03
9717740 Cortef method of use 62 2032-11-19
9717740 Cortef method of use 62 2032-11-19
9717740 Cortef method of use 62 2032-11-19
9717740 Cortef method of use 62 2032-11-19

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
10537585 Decadron formulation 25 2037-12-18
10159683 Decadron formulation 25 2034-05-23
10799642 Decadron formulation 31 2032-05-11
8409606 Decadron formulation 31 2030-05-14
8450287 Decadron formulation 38 2027-12-19
10022502 Decadron method of use 45 2034-06-22
10028965 Decadron method of use 45 2034-05-23
8563027 Decadron method of use 51 2030-02-12
11097061 Decadron method of use 53 2039-06-23
11304961 Decadron method of use 53 2037-12-18

Related